Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	288M 252M 234M 215M 406M 27.79B 412M 2.79B 1.09B 13.6B 1.08B 1.06B 46.97B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	384M 336M 312M 287M 541M 37.06B 549M 3.72B 1.46B 18.13B 1.44B 1.41B 62.64B	EV / Sales 2026 *	-	EV / Sales 2027 *	10.6x
Free-Float	95.04%	Yield 2026 *	-	Yield 2027 *	-

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
04-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
31/10/25	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
26/10/25	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
23/10/25	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
26/08/25	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI
18/08/25	Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman	CI
14/08/25	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
07-02	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
05-15	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ
04-30	Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform	PR
04-21	Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic	PR

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	31/05/2007
Linda Powers CEO	Chief Executive Officer	71	07/06/2011
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	31/12/1999

Northwest Biotherapeutics, Inc Share Price OTC Bulletin Board

Stocks

US66737P5017

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc

Latest news : Northwest Biotherapeutics, Inc

Press Releases: Northwest Biotherapeutics, Inc

Managers and Directors: Northwest Biotherapeutics, Inc

Bio Therapeutic Drugs

Financials

Company Profile

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	31/12/1997
Linda Powers CHM	Chairman	71	16/05/2007
Navid Malik BRD	Director/Board Member	57	31/03/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-0.43%	-1.26%	+52.13%	+85.69%	55.57B
ARGENX SE	-0.24%	-0.37%	+57.02%	+54.21%	54.26B
BIONTECH SE	-0.54%	-0.17%	-17.60%	-14.20%	23.35B
INSMED INCORPORATED	-1.82%	-2.89%	+3.61%	+421.21%	23.54B
WUXI BIOLOGICS (CAYMAN) INC.	+0.05%	+1.68%	+38.71%	-4.57%	20.32B
GENMAB A/S	+3.16%	+2.74%	+37.33%	-31.36%	17.36B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.08%	+3.77%	+36.92%	+593.96%	15.59B
PHARMAESSENTIA CORPORATION	+0.43%	-1.67%	+166.53%	+299.61%	14.96B
EXELIXIS, INC.	-2.03%	-1.03%	+23.63%	+176.42%	14.11B
Average	-0.04%	-0.23%	+44.25%	+175.66%	26.56B
Weighted average by Cap.	-0.18%	-0.23%	+43.92%	+137.55%

	2026 *	2027 *
Net sales	-	38.93M 34.11M 31.67M 29.1M 54.84M 3.76B 55.64M 377M 148M 1.84B 146M 143M 6.35B
Net income	-	-
Net Debt	96.08M 84.18M 78.15M 71.82M 135M 9.27B 137M 931M 364M 4.54B 361M 353M 15.67B	125M 109M 102M 93.39M 176M 12.06B 179M 1.21B 474M 5.9B 469M 459M 20.38B